Baseline 18F-FDG PET/CT Radiomics in Classical Hodgkin’s Lymphoma: The Predictive Role of the Largest and the Hottest Lesions

This study investigated the predictive role of baseline 18F-FDG PET/CT (bPET/CT) radiomics from two distinct target lesions in patients with classical Hodgkin’s lymphoma (cHL). cHL patients examined with bPET/CT and interim PET/CT between 2010 and 2019 were retrospectively included. Two bPET/CT target lesions were selected for radiomic feature extraction: Lesion_A, with the largest axial diameter, and Lesion_B, with the highest SUVmax. Deauville score at interim PET/CT (DS) and 24-month progression-free-survival (PFS) were recorded. Mann–Whitney test identified the most promising image features (p < 0.05) from both lesions with regards to DS and PFS; all possible radiomic bivariate models were then built through a logistic regression analysis and trained/tested with a cross-fold validation test. The best bivariate models were selected based on their mean area under curve (mAUC). A total of 227 cHL patients were included. The best models for DS prediction had 0.78 ± 0.05 maximum mAUC, with a predominant contribution of Lesion_A features to the combinations. The best models for 24-month PFS prediction reached 0.74 ± 0.12 mAUC and mainly depended on Lesion_B features. bFDG-PET/CT radiomic features from the largest and hottest lesions in patients with cHL may provide relevant information in terms of early response-to-treatment and prognosis, thus representing an earlier and stronger decision-making support for therapeutic strategies. External validations of the proposed model are planned.

[1]  S. Hohaus,et al.  Classical Hodgkin Lymphoma: A Joint Clinical and PET Model to Predict Poor Responders at Interim Assessment , 2022, Diagnostics.

[2]  L. Boldrini,et al.  Radiomics in Oncological PET Imaging: A Systematic Review—Part 2, Infradiaphragmatic Cancers, Blood Malignancies, Melanoma and Musculoskeletal Cancers , 2022, Diagnostics.

[3]  G. Perini,et al.  Baseline total metabolic tumor volume (TMTV) application in Hodgkin lymphoma: a review article , 2022, Clinical and Translational Imaging.

[4]  R. Boellaard,et al.  The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in 18F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma , 2022, The Journal of Nuclear Medicine.

[5]  M. Mayerhoefer,et al.  The role of 18F-FDG PET/CT radiomics in lymphoma , 2021, Clinical and Translational Imaging.

[6]  R. Boellaard,et al.  Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter? , 2021, The Journal of Nuclear Medicine.

[7]  R. Flavell,et al.  Treatment of sarcoidosis with cutaneous involvement with tofacitinib , 2021, medRxiv.

[8]  Alejandro F Frangi,et al.  Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  J. Yahalom,et al.  The presence of a bulky mediastinal mass of 7 cm or greater in diameter confers an adverse prognosis to patients with advanced Hodgkin lymphoma in case of negative interim PET/CT , 2021, Leukemia & lymphoma.

[10]  O. Alonso,et al.  Prognostic value of imaging markers from 18FDG-PET/CT in paediatric patients with Hodgkin lymphoma. , 2020, Nuclear medicine communications.

[11]  H. H. El-Bahnasawy,et al.  Correlation of texture feature analysis with bone marrow infiltration in initial staging of patients with lymphoma using 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography , 2020, Polish journal of radiology.

[12]  Xuejun Ma,et al.  Baseline SUVmax of 18F-FDG PET-CT indicates prognosis of extranodal natural killer/T-cell lymphoma , 2020, Medicine.

[13]  Y. Balagurunathan,et al.  High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. , 2020, Blood advances.

[14]  R. Advani,et al.  Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  Xuelei Ma,et al.  Current status and quality of radiomics studies in lymphoma: a systematic review , 2020, European Radiology.

[16]  S. Ansell Hodgkin lymphoma: A 2020 update on diagnosis, risk‐stratification, and management , 2020, American journal of hematology.

[17]  C. Nanni,et al.  Methodological framework for radiomics applications in Hodgkin’s lymphoma , 2020, European Journal of Hybrid Imaging.

[18]  Mauro Iori,et al.  Texture analysis and multiple-instance learning for the classification of malignant lymphomas , 2020, Comput. Methods Programs Biomed..

[19]  S. Q. Brunetto,et al.  Validation of a Multifocal Segmentation Method for Measuring Metabolic Tumor Volume in Hodgkin Lymphoma , 2020, The Journal of Nuclear Medicine Technology.

[20]  Georg Langs,et al.  Introduction to Radiomics , 2020, The Journal of Nuclear Medicine.

[21]  K. Chuang,et al.  Intratumor Heterogeneity Assessed by 18F-FDG PET/CT Predicts Treatment Response and Survival Outcomes in Patients with Hodgkin Lymphoma. , 2019, Academic radiology.

[22]  K. Chuang,et al.  Prognostic Value of Pretreatment Radiomic Features of 18F-FDG PET in Patients With Hodgkin Lymphoma. , 2019, Clinical nuclear medicine.

[23]  Alex Zwanenburg,et al.  Radiomics in nuclear medicine: robustness, reproducibility, standardization, and how to avoid data analysis traps and replication crisis , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  J. Zaucha,et al.  The role of PET/CT in the modern treatment of Hodgkin lymphoma. , 2019, Cancer treatment reviews.

[25]  T. Watabe,et al.  Volumetric and texture analysis on FDG PET in evaluating and predicting treatment response and recurrence after chemotherapy in follicular lymphoma , 2019, International Journal of Clinical Oncology.

[26]  C. Fuller,et al.  A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma , 2019, Scientific Reports.

[27]  R. Advani,et al.  Risk-adapted therapy for advanced-stage Hodgkin lymphoma. , 2018, Hematology. American Society of Hematology. Education Program.

[28]  M. Federico,et al.  Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  A. Nelson,et al.  Evaluation of a semi-automated whole body PET segmentation method applied to Diffuse Large B Cell Lymphoma , 2018 .

[30]  L. Cozzi,et al.  Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  Steve Y. Cho,et al.  Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better? , 2018, Nuclear Medicine and Molecular Imaging.

[32]  D. Mariano-Goulart,et al.  Association between textural and morphological tumor indices on baseline PET‐CT and early metabolic response on interim PET‐CT in bulky malignant lymphomas , 2017, Medical physics.

[33]  Stefan Leger,et al.  Image biomarker standardisation initiative version 1 . 4 , 2016, 1612.07003.

[34]  A. Afaq,et al.  CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin’s and aggressive non-hodgkin’s lymphomas , 2016, European Radiology.

[35]  S. Hohaus,et al.  Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET) , 2016, Annals of Nuclear Medicine.

[36]  Mauro Vallati,et al.  Moddicom: a complete and easily accessible library for prognostic evaluations relying on image features , 2015, 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

[37]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  R. Fisher,et al.  Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Carole Lartizien,et al.  Computer-Aided Staging of Lymphoma Patients With FDG PET/CT Imaging Based on Textural Information , 2012, IEEE Journal of Biomedical and Health Informatics.

[41]  Rathan M. Subramaniam,et al.  18F-FDG Metabolic Tumor Volume and Total Glycolytic Activity of Oral Cavity and Oropharyngeal Squamous Cell Cancer: Adding Value to Clinical Staging , 2012, The Journal of Nuclear Medicine.

[42]  Kristin D. Brockway,et al.  What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. , 2012, International journal of radiation oncology, biology, physics.

[43]  J. Radford,et al.  Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[44]  V. Diehl,et al.  Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Michel Meignan,et al.  Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.

[46]  Yan Liu,et al.  Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants , 2014, Medical Oncology.

[47]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[48]  V. Grégoire,et al.  Gradient-based delineation of the primary GTV on FDG-PET in non-small cell lung cancer: a comparison with threshold-based approaches, CT and surgical specimens. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.